Full Text Journal Articles by
Author Natalie Yl Ngoi

Advertisement

Find full text journal articles








A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).

Yong Jae Lee, Myong Cheol Lim, Byoung Gie Kim, Natalie Yl Ngoi, Chel Hun Choi, Sang Yoon Park, David Sp Tan, Yunjung Go, Jung Yun Lee,

<h4>Background</h4>The optimal treatment of <i>BRCA</i> wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in <i>BRCA</i> wild-type patients with platinum-sensitive recurrence. We ... Read more >>

J Gynecol Oncol (Journal of gynecologic oncology)
[2021, 32(2):e31]

Cited: 0 times

View full text PDF listing >>



A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).

Natalie Yl Ngoi, Valerie Heong, Samuel Ow, Wen Yee Chay, Hee Seung Kim, Chel Hun Choi, Geraldine Goss, Jeffrey C Goh, Bee Choo Tai, Diana Gz Lim, Nivashini Kaliaperumal, Veonice B Au, John E Connolly, Jae-Weon Kim, Michael Friedlander, Kidong Kim, David Sp Tan,

<h4>Background</h4>The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD<i>-</i>1)/programmed death-ligand 1 (PD-L1) axis in ovarian clear cell carcinoma.<h4>Primary objective</h4>To evaluate the efficacy of durvalumab (MEDI-4736) compared with standard ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2020, 30(8):1239-1242]

Cited: 1 time

View full text PDF listing >>



Advertisement

Exploiting replicative stress in gynecological cancers as a therapeutic strategy.

Natalie Yl Ngoi, Vignesh Sundararajan, David Sp Tan,

Elevated levels of replicative stress in gynecological cancers arising from uncontrolled oncogenic activation, loss of key tumor suppressors, and frequent defects in the DNA repair machinery are an intrinsic vulnerability for therapeutic exploitation. The presence of replication stress activates the DNA damage response and downstream checkpoint proteins including ataxia telangiectasia ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2020, 30(8):1224-1238]

Cited: 0 times

View full text PDF listing >>



Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.

Gloria Hj Chan, Yong Xiang Gwee, Jia Li Low, Yiqing Huang, Zhi Yao Chan, Joan Re Choo, Natalie Yl Ngoi, Yvonne LE Ang, Vaishnavi Muthu, Wan Qin Chong, Alvin Wong, Ross A Soo,

<h4>Background</h4>The importance of immune-checkpoint inhibitors (ICI) can no longer be understated since its move to front-line treatment in non-small cell lung cancer (NSCLC) in recent years. However, the safety and efficacy of ICI in special populations such as those with infections like tuberculosis (TB) and hepatitis B (HBV) remain unknown ... Read more >>

Lung Cancer (Lung cancer (Amsterdam, Netherlands))
[2020, 146:145-153]

Cited: 0 times

View full text PDF listing >>



The 4th European Society for Medical Oncology Asia Congress: bridging ultimate cancer care with real-world practice for the Asian practitioner in gynecological cancers.

Natalie Yl Ngoi, David Sp Tan,

J Gynecol Oncol (Journal of gynecologic oncology)
[2019, 30(2):e48]

Cited: 0 times

View full text PDF listing >>





Advertisement

Disclaimer
0.6065 s